Companies · Biotechnology

Mitogenetics, LLC

SIOUX FALLS · Biotechnology

Diligence memoA one-page analyst read on Mitogenetics, LLC — recommendation, valuation, rhythm, risks.
$9.2M
Total raised · real
4
Rounds
9.0×
Latest step-up
Top 46%
Sector rank · raised
Series A
Latest stage · inferred · Thu Nov 13 2014 00:00:00 GMT+0000 (Coordinated Universal Time)

Mitogenetics, LLC looks fair against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 0.69× the median modeled value of Series A Biotechnology companies in 2013–2015 (111 peers) — value vs value, same stage and era.
  • Within the normal band (69% of peer median) for its niche.
Dormant
  • Last raise 11.6 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.

Procedural diagnosis est. — rule-based common-sense checks over the filing pattern, issuer name, activity cadence, and surfaced operating evidence.

Issuer-vehicle patternmedium confidence

Mitogenetics, LLC behaves more like a recurring private-offering issuer than a conventional venture-backed operating company.

Issuer structure
Company-like
No recurring-offering pattern strong enough to override normal financing interpretation.
Lifecycle
56.5 yr record
Peak capital year was Undated with $5.0M across 1 filings.
Market position
ahead of 55% of Biotechnology peers
Capital scale is ahead of 55% of Biotechnology peers; modeled value is above 61% of peers by modeled value. Large capital with mid-pack modeled value can signal an issuer/program profile rather than operating-company growth.
Valuation reliability
Normal applicability
Stage/dilution valuation models are weakest when the issuer is broad-sector, recurring, or vehicle-like.
Operating evidence
Sparse
No clear CEO/founder/principal role is surfaced, so operating-company confidence is lower.
Data quality
Consistent
Canonical totals and visible filing detail are broadly aligned.
What triggered this
  • Legal name looks like an issuer vehicle rather than a product company.
  • No clearly named CEO/founder/principal role in the public records surfaced here.
  • No verified homepage on the profile yet.
  • Capital program peaked in Undated: $5.0M across 1 filings.
  • Largest single filing was $5.0M on .
How to read the page
  • Read this less like a startup funding journey and more like a capital-raising program.
  • Stage-based valuation and peer labels have lower applicability for this pattern.
  • The more important signal is lifecycle: repeated filings ended years ago, so current activity needs outside confirmation.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Mitogenetics, LLC is one of 4291 Biotechnology companies tracked from SIOUX FALLS. By capital raised it ranks mid-pack (ahead of 55% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$50M$100M$150M$200MSeries A · Raised $5.0M (real) Modeled valuation $10M (est)$5.0M$10MSeries ASeed · 2013-06-21 Raised $1.5M (real) Modeled valuation $66M (est)$1.5M$66MSeed2013Seed · 2014-11-13 Raised $275K (real) Modeled valuation $12M (est)$275K$12MSeed2014Seed · 2014-11-13 Raised $2.5M (real) Modeled valuation $110M (est)$2.5M$110MSeed2014+$1.5M+$275K+$2.5MCumulative $9.2M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series A$5.0M
Bridge · Series A-stage$1.5M · 2013smaller follow-on
Bridge · Series A-stage$275K · 2014smaller follow-on
Bridge · Series A-stage$2.5M · 2014smaller follow-on

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 67%.

Modeled valuation trajectory
$110.2M
Base estimate est.
$1.8M
Conservative case
$864.3M
Upside case
$12.4M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Aa $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Series A · modeled $10.0M · Seed · modeled $65.9M · 2013-06-21Seed · modeled $12.2M · 2014-11-13Seed · modeled $110.2M · 2014-11-132014
Model inputs · modeled:benchmark-stage-stepup-v1
20%
Dilution assumption
Implied ownership sold in the financing.
32%
Survival probability
14% low · 50% high
1.74×/yr
Annual markup
2.28×/yr upside case
6.0 yr
Elapsed time used
11.6 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
179 mo
Avg between rounds
$206K/yr
Capital velocity
56.5 yr
On record since
1970
First round
4
Rounds on file
How it compares to the market

Benchmarked against 4291 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 1.3× above median
This company$9.2M
Sector median$7.2M
Latest round — vs other Series A rounds in sector (real $, this stage) 0.5× of median
This company$2.5M
Sector median$5.4M
Modeled value — vs sector median (estimate, all stages) 1.7× above median
This company$110.2M
Sector median$64.2M

Raised more than 55% of sector peers (real $). Modeled value above 61% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #72 of 111.

This companyCohort peer
$10.0M$100.0M$1.0B$1.0M$10.0M$100.0MCapital raised (log)Dnanexus, Inc. · Series A Raised $31.6M · modeled $542.3M (est)Foresight Biotherapeutics, Inc. · Series A Raised $17.0M · modeled $542.3M (est)AuraSense Therapeutics, LLC · Series A Raised $33.6M · modeled $535.0M (est)Zyomyx Inc · Series A Raised $15.2M · modeled $514.1M (est)Thrasos Innovation Inc. · Series A Raised $14.0M · modeled $506.1M (est)Champions Oncology, Inc. · Series A Raised $36.8M · modeled $506.1M (est)Merganser Biotech, Inc. · Series A Raised $21.1M · modeled $473.5M (est)Progenics Pharmaceuticals Inc · Series A Raised $12.9M · modeled $467.2M (est)GeneWeave Biosciences, Inc. · Series A Raised $36.3M · modeled $441.0M (est)Aeglea BioTherapeutics Holdings, LLC · Series A Raised $15.8M · modeled $387.1M (est)Hydra Biosciences Inc · Series A Raised $10.5M · modeled $379.9M (est)Brainstorm Cell Therapeutics Inc. · Series A Raised $12.3M · modeled $379.6M (est)Mitogenetics, LLC (this company) Raised $9.2M · modeled $110.2M (est)Mitogenetics, LLC
CompanyStageRaised · realValue · estvs peer med.
Dnanexus, Inc.Series A$31.6M$542.3M3.41×
Foresight Biotherapeutics, Inc.Series A$17.0M$542.3M3.41×
AuraSense Therapeutics, LLCSeries A$33.6M$535.0M3.36×
Zyomyx IncSeries A$15.2M$514.1M3.23×
Thrasos Innovation Inc.Series A$14.0M$506.1M3.18×
Champions Oncology, Inc.Series A$36.8M$506.1M3.18×
Merganser Biotech, Inc.Series A$21.1M$473.5M2.98×
Progenics Pharmaceuticals IncSeries A$12.9M$467.2M2.94×
GeneWeave Biosciences, Inc.Series A$36.3M$441.0M2.77×
Aeglea BioTherapeutics Holdings, LLCSeries A$15.8M$387.1M2.43×
Hydra Biosciences IncSeries A$10.5M$379.9M2.39×
Brainstorm Cell Therapeutics Inc.Series A$12.3M$379.6M2.39×
Mitogenetics, LLC this companySeries A$9.2M$110.2M0.69×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Seed$1.5M2013-06-21$7.4M$65.9M90%
Seed$275K2014-11-13$1.4M$12.2M90%
Seed$2.5M2014-11-13$12.4M$110.2M90%
Series A$5.0M$22.7M$10.0M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Seed$1.5M2013-06-21
    • First recorded raise — entered as Seed.
  2. Seed$275K2014-11-13
    • Raised 17 mo later, in step with the ~14 mo sector norm.
    • Round 5.4× smaller than the prior — bridge or down round.
  3. Seed$2.5M2014-11-13
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 9.0× larger than the prior — scaling up.
Intelligence
2029 ~Q4
Modeled next raise · ~179mo cadence
$7.4M
Modeled next size est.range $4.8M$11.9M
9.0×
Last step-up
$206K/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Brian Minish4 other2014-11
Nick Sershen4 other2014-11
Steve Sershen2 other2014-11
Brad Nelson1 other2014-11
Brad Saeger1 other2014-11
Marcia Hendrickson1 other2013-06
Brad W. Nelson2013-06
E. Charles Brice2014-11
Evan W. Rayl2013-06
George Charles Stefano2014-11
Isaac J. Tessmer2013-06
Isaac Tessmer2014-11
Ivan W. Paulson2013-06
Leon J. Schwartz2013-06
Leon Schwartz2014-11
Mark Atwood2014-11
Mark Graczynski2014-11
Mark W. Atwood2013-06
Mark W. Graczynski2013-06
Max Charles Rogers2014-11
Steve W. Sershen2013-06
Walt Bones2014-11
William Switzer2014-11
William W. Switzer2013-06
Registry & provenance

Mitogenetics, LLC is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1511439
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Orchard Park at Arlington Highlands, LLCManufacturingSeries A$10.7M$27.2Mnetwork2 shared operators · same stage
Dermelle, LLCBiotechnologySeries A$9.4M$89.6Msame sector · same stage
Medigus Ltd.BiotechnologySeries A$8.6M$108.7Msame sector · same stage
Innervace, Inc.BiotechnologySeries A$10.0M$131.0Msame sector · same stage
AGI Scientific, LLCBiotechnologySeries A$10.0M$100.2Msame sector · same stage
ImmuneSensor Therapeutics, Inc.BiotechnologySeries A$10.0M$114.5Msame sector · same stage
Launchpad Therapeutics, Inc.BiotechnologySeries A$10.0M$111.4Msame sector · same stage
OncoImmune, Inc.BiotechnologySeries A$8.5M$108.5Msame sector · same stage
Frequently asked
How much funding has Mitogenetics, LLC raised?
Mitogenetics, LLC has raised approximately $9.2M in disclosed capital across 4 recorded financing rounds, aggregated from public filings.
What is Mitogenetics, LLC's estimated valuation?
Provath's modeled valuation for Mitogenetics, LLC is approximately $110.2M (modeled range $1.8M–$864.3M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Mitogenetics, LLC at?
Mitogenetics, LLC's latest modeled financing stage is Series A. Its most recent recorded round closed around Thu Nov 13.
What does Mitogenetics, LLC do and where is it based?
Mitogenetics, LLC operates in the Biotechnology sector, based in SIOUX FALLS.
Explore related

See where Mitogenetics, LLC sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Mitogenetics, LLC, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.